In this context, among participants with CKD and T2D in the Reduce Cardiovascular Events with Aranesp Therapy (TREAT) trial, elevated NT-proBNP and elevated troponin values were associated with a higher risk of end-stage renal disease [110]. Here, NPPB is linked to chronic kidney disease.